What the TGA's Compliance Principles for 2026-27 mean for supplement brands and practitioners

The TGA's previous compliance framework ran from 2023 to 2025 and was built around a list of specific regulated products and behaviours. It was largely reactive — enforcement followed complaints and investigations. The 2026–2027 framework represents a deliberate shift toward proactive, risk-based enforcement. The TGA has explicitly committed to monitoring digital platforms and social media for non-compliant advertising content, and to responding to emerging risks on a quarterly cycle rather than waiting for defined review periods.

The TGA's five core compliance principles for 2026–2027 are: Safeguarding Therapeutic Goods, Educate to Empower, Protect Those Most at Risk, Leverage Digital Capability, and Strengthen Enforcement.

From 1 January 2026, the 12 key priority focus areas are direct to consumer IVD kits, erectile dysfunction medications, foetal dopplers, listed medicine advertising, medicinal cannabis, melatonin, software as a medical device, substandard and falsified therapeutic goods, sunscreen, weight loss medications, therapeutic goods used in cosmetic procedures, and vaping goods.

Priority focus areas will be reviewed every quarter and updated as required. Quarterly reviews ensure that focus areas remain current. Any updates to focus areas will be based on emerging or ongoing risks to public health and safety, and on data and intelligence from TGA regulatory compliance activities.

The practical effect for supplement brands is that the enforcement environment is now more dynamic and less predictable than in any previous compliance period. A brand that reviewed its advertising against the 2023–2025 priorities and concluded it was compliant cannot assume that assessment holds under a quarterly-review framework that can add new priority areas in response to emerging risks identified by the TGA's digital monitoring systems.

1. Safeguarding Therapeutic Goods — digital advertising is the target
This principle aims to ensure public protection from unsafe products through proactively scrutinising advertising, particularly marketing content that appears on social media, and disrupting the availability of unapproved and falsified goods on digital platforms. For supplement brands, social media advertising — Instagram, TikTok, Facebook, YouTube — is the primary enforcement target under this principle. Content that has been live for years is within scope of proactive monitoring.

2. Educate to Empower — guidance will increase
The TGA has committed to releasing updated guidance materials throughout the 2026–2027 period. For supplement brands, this means the compliance education materials available will expand — and the TGA's expectation that brands have engaged with current guidance will increase alongside it.

3. Protect Those Most at Risk — health claims face heightened scrutiny
Advertising that targets vulnerable populations — people managing chronic conditions, weight, sleep, mental health — will receive heightened scrutiny under this principle. Supplement brands whose marketing is directed at these audiences should expect their content to be in a higher-priority monitoring category.

4. Leverage Digital Capability — automated monitoring is live
The TGA is increasing its ability to monitor online environments and detect non-compliant marketing activity using digital surveillance tools. This is not a future commitment — TGA monitoring of digital platforms and social media was confirmed as operational in the 2023–24 performance data. The 2026–2027 framework commits to expanding this capability.

5. Strengthen Enforcement — penalties and transparency will increase
The TGA has committed to visible, transparent enforcement action. Infringement notices will continue to be publicly disclosed. The 2023–24 data showed 147 notices totalling $2.20 million — this trajectory is expected to continue or accelerate under a strengthened enforcement principle.

Listed medicine advertising: the named priority for supplement brands

From 1 January 2026, listed medicine advertising is one of the 12 priority focus areas. This is the most direct signal the TGA has sent to supplement brands. AUST L listed medicines — vitamins, minerals, herbal medicines, and complementary medicines — are the core product category of the Australian supplement industry. Named inclusion as a priority focus area means the TGA has specifically allocated compliance and enforcement resources to monitoring advertising in this category.

The implications for supplement brands are concrete:

Social media content for Listed Medicines is within the active monitoring scope of the TGA's digital surveillance tools. Claims that exceed Permitted Indications for listed ingredients are a primary enforcement trigger. Missing mandatory statements — AUST number, sponsor name, 'always read the label' — remain among the most common infringement notice triggers. Influencer and practitioner content that a brand commissioned or facilitated is the brand's compliance responsibility.

The quarterly review cycle: why ongoing monitoring matters more than ever

For supplement brands, this cycle creates an important operational implication. A compliance review conducted against the January 2026 priority list may be incomplete by April 2026 if new product categories have been added. The TGA can add a new priority area in response to intelligence it receives from monitoring activities — and brands operating in adjacent categories may find themselves under heightened scrutiny without advance notice.

The brands best positioned in this environment are those with systematic pre-publication compliance processes — not those that conduct periodic audits. A process that reviews content before publication, generates an audit record, and routes high-risk findings to human review is structurally suited to a quarterly-review enforcement framework. A periodic manual audit is not.

What supplement brands need to do now

• Review current social media and website content against TGA Permitted Indications. The listed medicine advertising priority means existing content is within scope — not just new campaigns. Content that has been live for years can be identified by TGA monitoring tools and result in a removal request or infringement notice.
• Audit practitioner and influencer content associated with your brand. Under the TGA Advertising Code, a brand sponsor carries obligations to take reasonable steps to address non-compliant third-party content associated with their products. Practitioner and influencer posts that make claims beyond Permitted Indications are the brand's compliance exposure.
• Check mandatory statements across all channels. Every advertisement for a Listed Medicine must include the AUST L number, sponsor name, and 'always read the label and follow the directions for use' — across social media, websites, email marketing, and any other channel. Missing mandatory statements remain among the most common infringement triggers.
• Build pre-publication review into your content workflow. The quarterly enforcement cycle means the compliance landscape changes faster than an annual or biannual audit can track. Pre-publication review that generates an audit record for every piece of content is the structural response to a quarterly-review framework.

For health practitioners, this shift matters because it changes the probability calculation. Under a reactive enforcement model, the risk of non-compliant content being identified depended largely on whether someone complained. Under a proactive model with digital surveillance tools, content that has been live for years can be identified and acted upon without a complaint ever being made. The TGA confirmed in the 2026–2027 framework documentation that it is actively increasing its digital monitoring capability.

1. Safeguarding Therapeutic Goods
This principle explicitly targets the advertising of therapeutic goods on social media and digital platforms. It aims to ensure the public is protected from unsafe products through proactively scrutinising advertising, particularly marketing content that appears on social media, and disrupting the availability of unapproved and falsified goods, including those sold and advertised on digital platforms. For practitioners who post about Listed Medicines they recommend, this is the principle that is most directly relevant — social media content promoting therapeutic goods is an explicit enforcement target.

2. Educate to Empower
The TGA has committed to proactive guidance and education for industry, healthcare professionals, and consumers. This principle signals that the TGA will continue to issue guidance notes and compliance education materials through the 2026–2027 period, and that practitioners who can demonstrate engagement with that guidance will be in a stronger compliance position.

3. Protect Those Most at Risk
This principle focuses on protecting vulnerable populations — including patients who may be exposed to misleading health claims. For practitioners, it signals that advertising content targeting people with chronic health conditions, mental health conditions, or other vulnerabilities will attract heightened scrutiny.

4. Leverage Digital Capability
The TGA is increasing its ability to monitor online environments and detect non-compliant marketing activity using digital surveillance tools. This is the operational underpinning of the enforcement shift — the TGA is investing in capability to find non-compliant content proactively, not just respond to complaints.

5. Strengthen Enforcement
The TGA has committed to transparent, visible enforcement action. This means continued public disclosure of infringement notices, increased penalty activity, and removal actions. The 2023–24 data already showed this trajectory: 147 infringement notices totalling $2.20 million, 4,806 removal requests, 168 warning letters.

The priority focus areas that matter most to practitioners

Listed medicine advertising is the priority area most directly relevant to the majority of health practitioners in Australia. Listed Medicines include vitamins, minerals, herbal medicines, and complementary medicines — the product categories most commonly recommended and promoted by naturopaths, nutritionists, herbalists, TCM practitioners, and other natural medicine practitioners.

The inclusion of listed medicine advertising as a named priority signals that the TGA intends to actively monitor the advertising of these products in 2026 and 2027 — not only by supplement brands, but by practitioners who share content about these products on their professional platforms.

Cosmetic procedures is the priority area most relevant to nurses, cosmetic doctors, and aesthetic practitioners. The TGA has already issued infringement notices for advertising of cosmetic injectables and has signalled continued focus on this area.

Weight loss medications have already attracted active enforcement, with infringement notices issued to multiple businesses in early 2026 for unlawful advertising of prescription-only weight loss medicines.

What the quarterly review cycle means in practice

The quarterly update mechanism is a structural change from the previous framework. Under the 2023–2025 priorities, practitioners could review the list once and maintain compliance against a stable set of targets. Under the 2026–2027 framework, the priority areas can shift every 90 days.

The practical implication is that a compliance review conducted in January 2026 may not reflect the TGA's priorities in April 2026. Practitioners who review their advertising content once and assume ongoing compliance are exposed to the risk that new priority areas — including areas relevant to their practice — are added in subsequent quarterly updates.

Building a pre-publication compliance review process that applies consistently to all new content — not just a one-time audit — is the structural response to a quarterly-review enforcement framework.

How this affects practitioners who share product content online

Under the TGA Advertising Code 2021, any person who causes an advertisement for a therapeutic good to be published is an advertiser — regardless of whether they have a commercial relationship with the product. A practitioner who posts about a Listed Medicine they recommend is an advertiser for the purposes of that content.

The 2026–2027 framework's explicit focus on social media monitoring and digital surveillance means that practitioner product content — including Instagram posts, TikTok videos, Facebook recommendations, and website content — is within the active monitoring scope of the TGA's compliance activities.

The compliance obligations that apply to that content have not changed. What has changed is the probability and speed with which non-compliant content will be identified.

The TGA's priority focus areas are reviewed quarterly and may be updated after the date of this article. Always check the current TGA Compliance Principles page for the latest priority areas. This content does not constitute legal advice.

• Publishing without checking the complete advertisement’s overall impression.
• Treating one regulator’s checklist as coverage for every applicable framework.
• Failing to retain evidence showing what was reviewed and approved before publication.

CompliGUARD reviews the complete advertisement against TGA · AHPRA · FSANZ · ACCC requirements, identifies clause-level risks, proposes compliant wording, and retains the result in an audit trail before publication.